Objective Although it is well known that antipsychotics induce abnormal involuntary movements,large-scale data are still lacking on the relationship between such involuntary movement and dopamine D2 receptor blockade ...
详细信息
Objective Although it is well known that antipsychotics induce abnormal involuntary movements,large-scale data are still lacking on the relationship between such involuntary movement and dopamine D2 receptor blockade with antipsychotics in patients with *** objective of this study was to evaluate the relationship between antipsychotic-induced abnormal involuntary movement like tardive dyskinesia and estimated dopamine D2 receptor occupancy at peak and trough in patients with schizophrenia,using the dataset from the Clinical Antipsychotic Trials in Intervention Effectiveness(CATIE). Methods The dataset from 296 subjects(mean±SD age,38.7±10.5 years;risperidone,N=116;olanzapine,N=126;ziprasidone,N=54) who present a score of zero in the abnormal involuntary movement scale(AIMS) at the baseline in Phase 1 of the CATIE was *** and trough dopamine D2 receptor occupancy levels on the day of the assessment were estimated from plasma antipsychotic concentrations,using population pharmacokinetic analysis and our D2 prediction *** estimated peak and trough dopamine D2 receptor occupancy levels were compared between patients who presented an AIMS score of≥1 at the endpoint(AIMS+ group) and those who did not(AIMS- group),using independent t-test. Results Mean±SD daily doses of risperidone,olanzapine,and ziprasidone on the day of AIMS score assessments at the endpoint were 4.7±1.3 mg,21.6±7.4 mg,and 128.8±34.4 mg, ***±SD AIMS score at the endpoint was 0.47±*** were no significant differences in D2 receptor occupancy between the AIMS+ group(N=55) *** AIMS- group (N=241) at peak or trough in any of the three drugs(risperidone:75.2±6.3%vs.75.2±5.9%at peak and 71.9±8.9%vs.71.8±8.1%at trough;olanzapine,76.8±6.6%vs.74.9±8.1%at peak and 74.3±6.6%vs.71.8±10.2%at trough;ziprasidone,62.6±7.6%vs.61.0±9.8%at peak and 43.8±18.0%vs.34.8±19.3%at trough,respectively).Collectively,however,estimated dopamine D2 receptor occupancy levels at trough we
Objective Investigating the therapeutic effect of high-frequency repetitive transcranial magnetic stimulation(rTMS) on the mild cognitive impairment(MCI). Methods(1) Recruited 31 volunteers from Shijiazhuang City,who ...
详细信息
Objective Investigating the therapeutic effect of high-frequency repetitive transcranial magnetic stimulation(rTMS) on the mild cognitive impairment(MCI). Methods(1) Recruited 31 volunteers from Shijiazhuang City,who were diagnosed with mild cognitive impairment(MCI),and were randomly divided into treatment group(17) and control group(14);Magnetic stimulation site was located in the bilateral dorsolateral prefrontal area,the frequency is 20Hz,every 30 minutes(15 minutes on each side),5 times a week,eight courses,a total of 40 times;The control group received the same frequency,the use of pseudo-stimulating coil,it produced vibration and sound,but didn't generate a magnetic field.(3) before and after treatment,EEG test auditory oddball paradigm using event-related potentials(ERPs) recorded electrodes placed in Cz and Pz. Results(1) baseline comparison:all the indicators of the control group and the treatment group were not significantly different[MMSE score(t = 0.44,P> 0.05);P300 latency:Cz(t = 0.21,P> 0.05),Pz(t =0.27,P> 0.05);P300 Volatility:Cz(t = 0.72,P> 0.05),Pz(t = 0.460,P> 0.05);N200 latency:the Cz points(t = 0.40,P> 0.05),Pz(t= 0.55,P> 0.05);N200 Volatility:Cz(t = 0.93,P> 0.05),Pz(t = 0.65,P> 0.05)].(2) target P300:the latency and amplitude of the control group had no significant difference before and after treatment with[incubation period:Cz(t = 0.23,P> 0.05),Pz(t = 0.91,P> 0.05);Volatility:Cz(t= 1.11,P> 0.05),Pz(t= 1.01,P> 0.05)];Treatment group after the intervention incubation period becomes shorter[Cz(t = 3.12, P<0.01),Pz(t = 2.12,P<0.05)],increased volatility[Cz(t = 2.45,P<0.05),Pz(t = 2.31,P<0.05)]. (3) target N200:latency and amplitude of the control group before and after treatment had no significant difference[latency:Cz(t = 0.65,P> 0.05),Pz(t = 0.77,P> 0.05);Volatility:Cz(t = 0.42,P> 0.05),Pz(t = 0.81,P> 0.05)];Treatment group after the intervention incubation period in advance[Cz(t = 2.45,P<0.05),Pz(t = 2.22,P<0.05)],volatility reduce Cz(/ = 2.95,
Objectives To discuss the influences of light therapy on SD rats in the chronic stress *** provide theoretical basis for further studies. Methods 6-week-old SD rats were randomized into the control group,depression gr...
详细信息
Objectives To discuss the influences of light therapy on SD rats in the chronic stress *** provide theoretical basis for further studies. Methods 6-week-old SD rats were randomized into the control group,depression group, biological rhythm light(light 1) group,incandescent light(light 2) group and energy-saving light (light 3) *** rats completed the baseline measurement included the growth and development indicators(height and weight) and routine blood *** experiments included sucrose preference test,open field test,water maze test and formed swimming *** groups were performed ovariectomized surgery and completed the chronic stress depression model except the control *** 1,2 and 3 group were received light therapy of different parameters for 3 weeks,and the biological rhythm light was developed by Physics School of Peking *** that all indicators were remeasured and the rhythm of melatonin was also measured. Results i Physiological indicators:The depression group gained less weight than control group after chronic stress model and got some recover after light therapy(udepression=208.4,alight 1=220.0,alight 2=215.1,alight 3=228.9),the results were not significantly different,ii Behavioral indicators:a) Sucrose preference *** after the chronic stress model performed less sucrose than the control group(control group = 44.7±20.9,model group = 14.8±6.5,p <0.001);b) Open field *** groups gained higher scores than depression group,with no significant difference(depression group = 31.25±23.51,light a group = 52.59±25.36,p = 0.120;Light group 2 = 42.34±15.53,p = 0.230;optical group 3 = 41.71±27.69,p = 0.414);c) Water maze *** percent of distance in the 1st quadrant were higher in the light 1 and 3 group than depression group,light 2 group was lower,with no significant difference;d) Forced swimming *** percent of rest time was lower in light 2 and 3 group,higher in light 1 group after light therapy compar
Bipolar affective disorder is a mood disorder with different presentation at different phase of the *** is no universally agreed protocol in the treatment of this *** there are different treatment guidelines and recom...
详细信息
Bipolar affective disorder is a mood disorder with different presentation at different phase of the *** is no universally agreed protocol in the treatment of this *** there are different treatment guidelines and recommendations proposed by different professional organizations,e.g the CANMAT and WFSBP *** actual pattern of drug use may be different from place to *** study looks at the pattern of drug treatment in the treatment of this disorder in the outpatients in a psychiatric unit in a general hospital in Hong Kong.572 bipolar affective disorder patients attended the outpatient clinic in the year *** preliminary
For MDD treatment,generally speaking,different therapeutics(medication vs psycho-therapy), different treatment protocols show similar efficacy for mild to moderate *** similar overall efficacy,individuals may respond ...
详细信息
For MDD treatment,generally speaking,different therapeutics(medication vs psycho-therapy), different treatment protocols show similar efficacy for mild to moderate *** similar overall efficacy,individuals may respond to different treatments in greatly different *** that case,it is highly important to choose the right antidepressant treatment regimen as early as possible according to patients' symptoms. What is the individualized MDD treatment? How to choose the suitable individualized MDD
Background and Objective Bitopertin(RO4917838) is a glycine reuptake inhibitor that is postulated to improve N-methyl-D-aspartate-(NMDA) receptor hypofunction in the brain by increasing synaptic concentrations of *** ...
详细信息
Background and Objective Bitopertin(RO4917838) is a glycine reuptake inhibitor that is postulated to improve N-methyl-D-aspartate-(NMDA) receptor hypofunction in the brain by increasing synaptic concentrations of *** leads to normalization of the dysregulated glutamate,GABA and dopamine in neurocircuits relevant to *** compound is currently in Phase 3 for the treatment of *** objective of the study was to assess the pharmacokinetics(PK),safety and tolerability in Chinese healthy volunteers(HVs),
Background and Objective In the past several decades,the use of high antipsychotic doses has been a continuously controversial topic in both clinical practice and *** most of the studies and treatment recommendations ...
详细信息
Background and Objective In the past several decades,the use of high antipsychotic doses has been a continuously controversial topic in both clinical practice and *** most of the studies and treatment recommendations do not support this practice,antipsychotic drugs are still widely prescribed in high doses in the treatment of *** example, 15.4%-41%of adult schizophrenia inpatients in the USA and in Europe receive high-dose *** could not locate any large-scale,pharmaco-epidemiological surveys on high antipsychotic doses in older patients with *** study aimed to examine the use of high doses of antipsychotic medications(>/=600 mg/day CPZeq) in older Asian patients with
OBJECTIVE We tested whether a polymorphism in the promoter region of the serotonin transporter correlated to episode,gender,severity,and suicidal behavior in depression in Chinese Han people. METHODS Polymerase chain ...
详细信息
OBJECTIVE We tested whether a polymorphism in the promoter region of the serotonin transporter correlated to episode,gender,severity,and suicidal behavior in depression in Chinese Han people. METHODS Polymerase chain reaction was used to detect promoter polymorphisms in 150 depressed patients(patient group) and 150 normal *** patients consisted of 74 males and 76 females,with an average age of 45.6±12.3 years and were diagnosed by experienced psychiatrists according to ICD-10 diagnosis criteria. RESULTS The frequency of5-HTTLPR genotypes SS,LS(26.0%vs 20.0%;52.7%vs 46.0%)
Background To compare autonomic response to threatening stimuli between patients with panic disorder(PD) and healthy volunteers by using 5-minute recordings of heart rate variability(HRV). Methods Twenty-seven patient...
Background To compare autonomic response to threatening stimuli between patients with panic disorder(PD) and healthy volunteers by using 5-minute recordings of heart rate variability(HRV). Methods Twenty-seven patients with PD and twenty healthy controls were *** first 5-minute measurement of HRV was conducted at resting *** measure during threatening stimuli was conducted while participants were viewing 15 threatening *** analyses measures included high frequency(HF;0.15-0.4 HZ) component,low frequency(LF;0.04-0.15 Hz) component,and LF/HF ratio. Results There was no significant HRV difference between the two groups at the resting state. During threatening stimuli,PD group had significantly higher LF power and LF/HF ratio and significantly lower HF power than healthy controls(for all,p
Objective To evaluate the efficacy and safety of acamprosate in treating patients with alcohol dependence. Methods A randomized,double-blind,placebo-controlled multicenter clinical trial was *** diagnosis of alcohol d...
详细信息
Objective To evaluate the efficacy and safety of acamprosate in treating patients with alcohol dependence. Methods A randomized,double-blind,placebo-controlled multicenter clinical trial was *** diagnosis of alcohol dependence was made according to the Diagnostic and Statistical Manual of Mental Disorders,Fourth Edition(DSM-IV) *** 230 patients received 12 weeks treatment with either acamprosate(weight<60 kg,1332 mg/d;weight>60 kg, 1998 mg/d.n=116) or placebo(n=l14).The primary efficacy measures were the cumulative abstinence duration(CAD) and corrected cumulative abstinence duration(CCAD),relapse rate of every visit,time to first *** secondary efficacy measures were the drinking times,the
暂无评论